Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages

Clinical Immunology

Volumn 142, Issue 3, 2012, Pages 296-307

  Kadowaki, Takeshi ^a   Arikawa, Tomohiro ^a   Shinonaga, Rika ^a   Oomizu, Souichi ^a   Inagawa, Hiroyuki ^b   Soma, Genichiro ^b   Niki, Toshiro ^a   Hirashima, Mitsuomi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Anti tumor immunity; Galectin 9; M CSF; NK cell; PDC like m

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; ECALECTIN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERFERON REGULATORY FACTOR 7; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IN VITRO STUDY; LUNG CANCER; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL LIKE MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; GALECTINS; LUNG NEOPLASMS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84857359975     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.11.006     Document Type: Article

References (47)

1. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., Gitt M.A., Hirabayashi J., Hughes C., Kasai K., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
2. Gray C.A., Adelson D.L., Bazer F.W., Burghardt R.C., Meeusen E.N., Spencer T.E. Discovery and characterization of an epithelial-specific galectin in the endometrium that forms crystals in the trophectoderm. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7982-7987.
3. Asakura H., Kashio Y., Nakamura K., Seki M., Dai S., Shirato Y., Abedin M.J., Yoshida N., Nishi N., Imaizumi T., Saita N., Toyama Y., Takashima H., Nakamura T., Ohkawa M., Hirashima M. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J. Immunol. 2002, 169:5912-5918.
4. Zick Y., Eisenstein M., Goren R.A., Hadari Y.R., Levy Y., Ronen D. Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj. J. 2004, 19:517-526.
5. Kashio Y., Nakamura K., Abedin M.J., Seki M., Nishi N., Yoshida N., Nakamura T., Hirashima M. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 2003, 170:3631-3636.
6. Perillo N.L., Pace K.E., Seilhamer J.J., Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature 1995, 378:736-739.
7. Matsumoto R., Matsumoto H., Seki M., Hata M., Asano Y., Kanegasaki S., Stevens R.L., Hirashima M. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 1998, 273(1998):16976-16984.
8. Seki M., Oomizu S., Sakata K.M., Sakata A., Arikawa T., Watanabe K., Ito K., Takeshita K., Niki T., Saita N., Nishi N., Yamauchi A., Katoh S., Matsukawa A., Kuchroo V., Hirashima M. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 2008, 127:78-88.
9. Dai S.Y., Nakagawa R., Itoh A., Murakami H., Kashio Y., Abe H., Katoh S., Kontani K., Kihara M., Zhang S.L., Hata T., Nakamura T., Yamauchi A., Hirashima M. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J. Immunol. 2005, 175:2974-2981.
10. Nobumoto A., Nagahara K., Oomizu S., Katoh S., Nishi N., Takeshita K., Niki T., Tominaga A., Yamauchi A., Hirashima M. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008, 18:735-744.
11. Nagahara K., Arikawa T., Oomizu S., Kontani K., Nobumoto A., Tateno H., Watanabe K., Niki T., Katoh S., Miyake M., Nagahata S., Hirabayashi J., Kuchroo V.K., Yamauchi A., Hirashima M. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 2008, 181:7660-7669.
12. Nobumoto A., Oomizu S., Arikawa T., Katoh S., Nagahara K., Miyake M., Nishi N., Takeshita K., Niki T., Yamauchi A., Hirashima M. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin. Immunol. 2009, 130:322-330.
13. Kojima K., Arikawa T., Saita N., Goto E., Tsumura S., Tanaka R., Masunaga A., Niki T., Oomizu S., Hirashima M., Kohrogi H. Galectin-9 attenuates acute lung injury by expanding CD14- plasmacytoid dendritic cell-like macrophages. Am. J. Respir. Crit. Care Med. 2011, 184:328-339.
14. Sunderkotter C., Steinbrink K., Goebeler M., Bhardwaj R., Sorg C. Macrophages and angiogenesis. J. Leukoc. Biol. 1994, 55:410-422.
15. Evans R., Duffy T.M., Blake S.S., Lin H.S. Regulation of systemic macrophage IL-1 gene transcription: the involvement of tumor-derived macrophage growth factor, CSF-1. J. Leukoc. Biol. 1989, 46:428-433.
16. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., Pasqualini F., Nebuloni M., Chiabrando C., Mantovani A., Allavena P. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 2010, 185:642-652.
17. Liu Y.Y., Sun L.C., Wei J.J., Li D., Yuan Y., Yan B., Liang Z.H., Zhu H.F., Xu Y., Li B., Song C.W., Liao S.J., Lei Z., Zhang G.M., Feng Z.H. Tumor cell-released TLR4 ligands stimulate Gr-1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. J. Immunol. 2010, 185:2773-2782.
18. Kawamura K., Komohara Y., Takaishi K., Katabuchi H., Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int. 2009, 59:300-305.
19. Nishi N., Itoh A., Fujiyama A., Yoshida N., Araya S., Hirashima M., Shoji H., Nakamura T. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett. 2005, 579:2058-2064.
20. Kuroda E., Ho V., Ruschmann J., Antignano F., Hamilton M., Rauh M.J., Antov A., Flavell R.A., Sly L.M., Krystal G. SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J. Immunol. 2009, 183:3652-3660.
21. Piriou L., Chilmonczyk S., Genetet N., Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000, 41:289-297.
22. Biswas S.K., Sica A., Lewis C.E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 2008, 180:2011-2017.
23. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009, 86:1065-1073.
24. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267:204-215.
25. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
26. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252.
27. Wang F., He W., Zhou H., Yuan J., Wu K., Xu L., Chen Z.K. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell. Immunol. 2007, 250(2007):68-74.
28. Anderson A.C., Anderson D.E., Bregoli L., Hastings W.D., Kassam N., Lei C., Chandwasker R., Karman J., Su E.W., Hirashima M., Bruce J.N., Kane L.P., Kuchroo V.K., Hafler D.A. Promotion of tissue inflammation by the immune recptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
29. Nagasawa M., Schmidlin H., Hazekamp M.G., Schotte R., Blom B. Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B. Eur. J. Immunol. 2008, 38:2389-2400.
30. Schotte R., Rissoan M.C., Bendriss-Vermare N., Bridon J.M., Duhen T., Weijer K., Briere F., Spits H. The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development. Blood 2003, 101:1015-1023.
31. Cisse B., Caton M.L., Lehner M., Maeda T., Scheu S., Locksley R., Holmberg D., Zweier C., den Hollander N.S., Kant S.G., Holter W., Rauch A., Zhuang Y., Reizis B. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 2008, 135:37-48.
32. Esashi E., Watowich S.S. Dendritic cells: transcriptional control of plasmacytoid dendritic cell development by E2-2. Immunol. Cell Biol. 2009, 87:1-2.
33. Uematsu S., Sato S., Yamamoto M., Hirotani T., Kato H., Takeshita F., Matsuda M., Coban C., Ishii K.J., Kawai T., Takeuchi O., Akira S. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J. Exp. Med. 2005, 201:915-923.
34. Kawai T., Sato S., Ishii K.J., Coban C., Hemmi H., Yamamoto M., Terai K., Matsuda M., Inoue J., Uematsu S., Takeuchi O., Akira S. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 2004, 5:1061-1068.
35. Wendland M., Czeloth N., Mach N., Malissen B., Kremmer E., Pabst O., Forster R. CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6347-6352.
36. Asselin-Paturel C., Brizard G., Pin J.J., Briere F., Trinchieri G. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J. Immunol. 2003, 171:6466-6477.
37. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
38. Rankin L., Belz G.T. Diverse roles of inhibitor of differentiation 2 in adaptive immunity. Clin. Dev. Immunol. 2011, 2011:281569.
39. Tailor P., Tamura T., Ozato K. IRF family proteins and type I interferon induction in dendritic cells. Cell Res. 2006, 16:134-140.
40. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
41. Krausgruber T., Blazek K., Smallie T., Alzabin S., Lockstone H., Sahgal N., Hussell T., Feldmann M., Udalova I.A. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011, 12:231-238.
42. Wang F., Wan L., Zhang C., Zheng X., Li J., Chen Z.K. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology 2009, 214:342-349.
43. Barchet W., Cella M., Colonna M. Plasmacytoid dendritic cells-virus experts of innate immunity. Semin. Immunol. 2005, 17:253-261.
44. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
45. Grouard G., Rissoan M.C., Filgueira L., Durand I., Banchereau J., Liu Y.J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 1997, 185:1101-1111.
46. Bjorck P., Leong H.X., Engleman E.G. Plasmacytoid dendritic cell dichotomy: identification of IFN-alpha producing cells as a phenotypically and functionally distinct subset. J. Immunol. 2011, 186:1477-1485.
47. Kelsall B. Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. Mucosal Immunol. 2008, 1:460-469.